000			01678 a2200493 4500
005			20250516024537.0
264		0	_c20110414
008			201104s 0 0 eng d
022			_a1531-4995
024	7		_a10.1002/lary.21415 _2doi
040			_aNLM _beng _cNLM
100	1		_aKarnezis, Tom T
245	0	0	_aEfficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. _h[electronic resource]
260			_bThe Laryngoscope _cMar 2011
300			_a636-8 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdministration, Intranasal
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAngiogenesis Inhibitors _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aBevacizumab
650	0	4	_aCombined Modality Therapy
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aEpistaxis _xdrug therapy
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInjections
650	0	4	_aLaser Coagulation
650	0	4	_aLasers, Solid-State _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNasal Mucosa _xdrug effects
650	0	4	_aNasal Sprays
650	0	4	_aRecurrence
650	0	4	_aRetrospective Studies
650	0	4	_aTelangiectasia, Hereditary Hemorrhagic _xdrug therapy
650	0	4	_aYoung Adult
700	1		_aDavidson, Terence M
773	0		_tThe Laryngoscope _gvol. 121 _gno. 3 _gp. 636-8
856	4	0	_uhttps://doi.org/10.1002/lary.21415 _zAvailable from publisher's website
999			_c20620368 _d20620368